(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 19.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Mannkind's revenue in 2024 is $198,962,000.On average, 4 Wall Street analysts forecast MNKD's revenue for 2024 to be $65,687,829,442, with the lowest MNKD revenue forecast at $64,786,795,950, and the highest MNKD revenue forecast at $67,280,051,892. On average, 4 Wall Street analysts forecast MNKD's revenue for 2025 to be $79,377,751,576, with the lowest MNKD revenue forecast at $75,752,254,568, and the highest MNKD revenue forecast at $83,072,475,648.
In 2026, MNKD is forecast to generate $92,642,576,277 in revenue, with the lowest revenue forecast at $88,156,338,090 and the highest revenue forecast at $98,378,146,617.